CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J. Harrison, Piers Blombery, Marzia Rahman et al.|New England Journal of Medicine|2025Cited by 58
Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-upRocío Montes de, Enrique Zudaire, Junchen Gu et al.|Blood|2023Cited by 9
Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple MyelomaYi Lin, Rui Wang, Saad Z. Usmani et al.|Transplantation and Cellular Therapy|2024Cited by 1